FinlayAY. Current severe psoriasis and the rule of tens. Br J Dermatol. 2005;152(5):861-867. doi:10.1111/j.1365-2133.2005.06502.x.
2.
GolbariNMvan der WaltJMBlauveltARyanCvan de KerkhofPKimballAB. Psoriasis severity: Commonly used clinical thresholds may not adequately convey patient impact. J Eur Acad Dermatol Venereol JEADV. 2021;35(2):417-421. doi:10.1111/jdv.16966.
3.
StroberBRyanCvan de KerkhofP, et al.Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117-122. doi:10.1016/j.jaad.2019.08.026.
4.
MerolaJFQureshiAHusniME. Underdiagnosed and undertreated psoriasis: Nuances of treating psoriasis affecting the scalp, face, intertriginous areas, genitals, hands, feet, and nails. Dermatol Ther. 2018;31(3):e12589. doi:10.1111/dth.12589.
5.
ArmstrongAWKoningJWRowseSTanHMamoloCKaurM. Under-treatment of patients with moderate to severe psoriasis in the United States: Analysis of medication usage with health plan data. Dermatol Ther. 2017;7(1):97-109. doi:10.1007/s13555-016-0153-2.
6.
BrownstoneNDHongJMoscaM, et al.Biologic treatments of psoriasis: An update for the clinician. Biol Targets & Ther. 2021;15:39-51. doi:10.2147/BTT.S252578.
7.
GuptaSGarbariniSNazarethTKhilfehICostantinoHKaplanD. Characterizing outcomes and unmet needs among patients in the United States with mild-to-moderate plaque psoriasis using prescription topicals. Dermatol Ther. 2021;11(6):2057-2075. doi:10.1007/s13555-021-00620-x.
